Edward Stites

Assistant Professor

Integrative Biology Laboratory

Salk Institute for Biological Studies - Edward Stites

Current Research


The Problem

Multiple checks and balances in our cellular programming mean that cancer develops only after a number of processes go awry. This is why understanding cancer at a systems level, how multiple cellular factors interact, may be able to uncover new ideas for how to treat cancer. Faulty cell signaling networks, which usher signals into the nucleus from outside the cell to change gene expression, have been implicated in cancer. Multiple drugs that target these networks have been developed and are benefitting cancer patients. A better understanding of the behavior of these networks and their component proteins may facilitate the development of treatments that benefit more patients, and that provide more benefit to each patient.

The Approach

Edward Stites uses mathematical and computational models to study the behaviors of signaling networks implicated in cancer. Signaling proteins operate within large, complex networks and even when the roles of individual proteins are well understood, the behavior of the network of proteins can be difficult to predict. Stites uses his methods to reveal the how these networks promote cancer and respond to treatment. Mathematical models help illuminate the unknowns. They help formulate new hypotheses for experimental testing. The incorporation of data-driven models into cancer research should enable quicker and more efficient progress.


The Innovations and Discoveries

Stites developed a mathematical model of the RAS signaling pathway that revealed multiple unexpected behaviors by the most common activating mutations in human cancer. This work also demonstrated how mathematical models can be used to study cancer-promoting mutations.

It has become clear that not all mutations to the same gene behave similarly. Stites’ models are capable of predicting the behaviors of different mutations to the same gene, including different responses to treatment. This suggests a role for these computational approaches in personalized cancer medicine.

Stites’ modeling found that certain mutations (such as mutations in the NF1 tumor suppressor gene) amplified the effects of other gene mutations, suggesting that certain combinations of mutations work together to drive cancer. These results were borne out with experiments using cancer cells and were observed in sequenced cancer genomes.

Support Salk Research

Donate

Education

2015 Clinical Pathology Residency, Washington University, St. Louis, MO
Physician Scientist Training Program
2010 Doctor of Medicine, University of Virginia, Charlottesville, VA
2008 Doctor of Philosophy, Biophysics, University of Virginia, Charlottesville, VA
Medical Scientist Training Program
1998 Bachelor of Science, Mathematics, University of Kentucky, Lexington, KY
Honors Program


Awards & Honors

  • 2015 NIH Loan Repayment Program, Clinical Research (2015-2016)

  • 2014 Pathology Informatics 2014 Travel Award, Association of Pathology Informatics

  • 2011 NIH Loan Repayment Program, Clinical Research (2011-2013)

  • 2011 AACR Scholar in Training Award; AACR/NCI Conference on Systems Biology

  • 2010 Randy Pausch Scholar
  • 2009 Pathology Honor Society
  • 2009 American Medical Association Seed Grant (2009-2010)


Science Guide